Tag Archives: biotechnology news

Ariad: “The Future Ain’t What It Used To Be!” Judge Linn’s Concurrence and the Abuse and Neglect of the Enablement Requirement at the Federal Circuit

In my post of April 13, 2009, I concluded with a brief summary of Judge Linn’s cogent concurrence, and noted that I would revisit it. Judge Linn does not believe that it was ever necessary for the court to graft … Continue reading

Posted in Written Description Requirements (WDR) | Tagged , , , , , , , , , | Leave a comment

Federal Circuit Throws a Wrench into “Mechanism of Action” Claims

A three-judge panel of the Court of Appeals for the Federal Circuit recently decided Ariad Pharmaceuticals, Inc. et al. v. Eli Lilly & Company, appeal no. 2008-1248 (Fed. Cir. April 3, 2009), involving Blatimore et al. (U.S. Pat. No. 6,410,516). … Continue reading

Posted in Written Description Requirements (WDR) | Tagged , , , , , , , , , , , , | Leave a comment